Cargando…
Euglycemic Diabetic Ketoacidosis in a Lung Cancer Patient Using Empagliflozin
Diabetic ketoacidosis is a leading cause of morbidity and mortality in diabetic patients, and its diagnosis should be timely and accurate. SGLT2 inhibitors are a new class of antidiabetic medications that increase the renal excretion of glucose. It is thought that increased urinary excretion of gluc...
Autores principales: | Sexe, Jordan, Mayes, Chadwick, Tofts, Peter |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7350083/ https://www.ncbi.nlm.nih.gov/pubmed/32695525 http://dx.doi.org/10.1155/2020/7437892 |
Ejemplares similares
-
Empagliflozin: Euglycemic and hyperglycaemic diabetic ketoacidosis: case report
Publicado: (2021) -
Empagliflozin induced euglycemic diabetic ketoacidosis. A case reports
por: Altowayan, Waleed M.
Publicado: (2022) -
The DKA that wasn't: a case of euglycemic diabetic ketoacidosis due to empagliflozin
por: Candelario, Nellowe, et al.
Publicado: (2016) -
Euglycemic Diabetic Ketoacidosis after a Single Dose of Empagliflozin in a Patient with Pancreatitis
por: Calçada, Marta Brandão, et al.
Publicado: (2021) -
Euglycemic diabetic ketoacidosis caused by empagliflozin complicated by failure to thrive in a geriatric patient
por: Rathore, Azeem, et al.
Publicado: (2023)